Tolmetin

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

托美丁是一种非甾体类抗炎药。托美丁的作用机制是作为环加氧酶抑制剂。

Tolmetin is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of tolmetin is as a Cyclooxygenase Inhibitor. The chemical classification of tolmetin is Nonsteroidal Anti-inflammatory Compounds.(In Vitro):Tolmetin (0.25 mM) does not attenuate lipid peroxidation in rat brain homogenate. Tolmetin (0.25, 0.5, 0.75, 1 mM) shows radical scavenging properties but without superoxide anion generation in rat brain homogenat.Tolmetin (0.001-100 μM) shows anticancer activity againts HT-29 colon cancer cell line in a dose-dependent manner.Tolmetin (0-100 μM) shows no effect on osteoblast growth.(In Vivo):Tolmetin (30,100 mg/kg; gavage; single dose or twice daily for 3 and 14 days) shows maximal ulcerogenic effect 4 h after the single dose, while potently decreases after 3 and 14 days of repeated administration in male Wistar rats weighing 180-200 g. Tolmetin causes gastric lesions in 100 mg/kg.Tolmetin (5 mg/kg twice a day for 5 days) pre-treatment considerably attenuates quinolinic acid (QA)-induced neurotoxicity.

Tolmetin (0.25 mM) does not attenuate lipid peroxidation in rat brain homogenate. Tolmetin (0.25, 0.5, 0.75, 1 mM) shows radical scavenging properties but without superoxide anion generation in rat brain homogenat. Tolmetin (0.001-100 μM) shows anticancer activity againts HT-29 colon cancer cell line in a dose-dependent manner.

Tolmetin (30,100 mg/kg; gavage; single dose or twice daily for 3 and 14 days) shows maximal ulcerogenic effect 4 h after the single dose, while potently decreases after 3 and 14 days of repeated administration in male Wistar rats weighing 180-200 g. Tolmetin causes gastric lesions in 100 mg/kg. Tolmetin (5 mg/kg twice a day for 5 days) pre-treatment considerably attenuates quinolinic acid (QA)-induced neurotoxicity.

——

Chromatin/Epigenetic

COX

COX-1| COX-2

——

——

26171-23-3

257.28

C15H15NO3

>98% (HPLC)

DMSO: 10 mM

CN1C(CC(O)=O)=CC=C1C(=O)C1=CC=C(C)C=C1

——

(-20℃)

With Ice Pack

≥ 2 years